Foslevodopa

CHEMBL4594379 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
277.2 g/mol
LogP
-4.0
Phase
4

A prodrug form of levodopa delivered under the skin to provide steady levels of the medication for Parkinson's disease. It helps reduce motor fluctuations in patients who experience unpredictable 'on' and 'off' periods.

Molekularmasse

277,1700 g/mol

LogP

-4,00

TPSA

150,00 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Wirkmechanismus

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

N[C@@H](Cc1ccc(OP(=O)(O)O)c(O)c1)C(=O)O

InChI

InChI=1S/C9H12NO7P/c10-6(9(12)13)3-5-1-2-8(7(11)4-5)17-18(14,15)16/h1-2,4,6,11H,3,10H2,(H,12,13)(H2,14,15,16)/t6-/m0/s1

Molecular Formula

C9H12NO7P

HBD / HBA

5 / 8

Rotierbare Bindungen

5

Schwere Atome

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A prodrug form of levodopa delivered under the skin to provide steady levels of the medication for Parkinson's disease. It helps reduce motor fluctuations in patients who experience unpredictable 'on' and 'off' periods.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Foslevodopa is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594379. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 127766. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.